Sinphar Pharmaceutical Co Ltd (1734) - Total Assets

Latest as of March 2026: NT$6.42 Billion TWD ≈ $202.30 Million USD

Based on the latest financial reports, Sinphar Pharmaceutical Co Ltd (1734) holds total assets worth NT$6.42 Billion TWD (≈ $202.30 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 1734 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.

Sinphar Pharmaceutical Co Ltd - Total Assets Trend (2002–2025)

This chart illustrates how Sinphar Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore Sinphar Pharmaceutical Co Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.

Sinphar Pharmaceutical Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2025)

Sinphar Pharmaceutical Co Ltd's total assets of NT$6.42 Billion consist of 41.1% current assets and 58.9% non-current assets.

Asset Category	Amount (TWD)	% of Total Assets
Cash & Equivalents	NT$0.00	14.0%
Accounts Receivable	NT$713.86 Million	11.6%
Inventory	NT$724.69 Million	11.8%
Property, Plant & Equipment	NT$0.00	0.0%
Intangible Assets	NT$59.52 Million	1.0%
Goodwill	NT$0.00	0.0%

Asset Composition Trend (2002–2025)

This chart illustrates how Sinphar Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 1734 market cap overview.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Sinphar Pharmaceutical Co Ltd's current assets represent 41.1% of total assets in 2025, an increase from 0.0% in 2002.
Cash Position: Cash and equivalents constituted 14.0% of total assets in 2025, up from 6.1% in 2002.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 5.0% in 2002.
Asset Diversification: The largest asset category is inventory at 11.8% of total assets.

Sinphar Pharmaceutical Co Ltd Competitors by Total Assets

Key competitors of Sinphar Pharmaceutical Co Ltd based on total assets are shown below.

Company	Country	Total Assets
Ascendis Pharma AS NASDAQ:ASND	USA	$2.01 Billion
Biomarin Pharmaceutical Inc NASDAQ:BMRN	USA	$8.59 Billion
Spyre Therapeutics Inc. NASDAQ:SYRE	USA	$763.95 Million
3SBio Inc F:83B	Germany	€36.25 Billion
Soleno Therapeutics Inc NASDAQ:SLNO	USA	$608.39 Million
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	China	CN¥4.48 Billion
Novavax Inc NASDAQ:NVAX	USA	$1.04 Billion
BB Biotech AG SW:BION	Switzerland	CHF2.64 Billion

Sinphar Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	2.37	2.54	1.90
Quick Ratio	1.68	1.84	1.42
Cash Ratio	0.00	0.00	0.00
Working Capital	NT$1.59 Billion	NT$1.61 Billion	NT$1.33 Billion

Sinphar Pharmaceutical Co Ltd - Advanced Valuation Insights

This section examines the relationship between Sinphar Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	1.74
Latest Market Cap to Assets Ratio	0.03
Asset Growth Rate (YoY)	-2.3%
Total Assets	NT$6.15 Billion
Market Capitalization	$191.15 Million USD

Valuation Analysis

Below Book Valuation: The market values Sinphar Pharmaceutical Co Ltd's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: Sinphar Pharmaceutical Co Ltd's assets decreased by 2.3% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Sinphar Pharmaceutical Co Ltd (2002–2025)

The table below shows the annual total assets of Sinphar Pharmaceutical Co Ltd from 2002 to 2025.

Year	Total Assets	Change
2025-12-31	NT$6.15 Billion ≈ $193.85 Million	-2.31%
2024-12-31	NT$6.30 Billion ≈ $198.43 Million	+0.75%
2023-12-31	NT$6.25 Billion ≈ $196.94 Million	+1.07%
2022-12-31	NT$6.19 Billion ≈ $194.87 Million	-0.57%
2021-12-31	NT$6.22 Billion ≈ $195.99 Million	+1.53%
2020-12-31	NT$6.13 Billion ≈ $193.03 Million	+3.56%
2019-12-31	NT$5.92 Billion ≈ $186.40 Million	+0.65%
2018-12-31	NT$5.88 Billion ≈ $185.19 Million	-2.73%
2017-12-31	NT$6.04 Billion ≈ $190.39 Million	-2.63%
2016-12-31	NT$6.21 Billion ≈ $195.54 Million	-2.82%
2015-12-31	NT$6.39 Billion ≈ $201.21 Million	-1.20%
2014-12-31	NT$6.46 Billion ≈ $203.65 Million	+13.33%
2013-12-31	NT$5.70 Billion ≈ $179.69 Million	+25.74%
2012-12-31	NT$4.54 Billion ≈ $142.90 Million	-2.22%
2011-12-31	NT$4.64 Billion ≈ $146.14 Million	+24.92%
2010-12-31	NT$3.71 Billion ≈ $116.99 Million	+3.60%
2009-12-31	NT$3.58 Billion ≈ $112.93 Million	-0.25%
2008-12-31	NT$3.59 Billion ≈ $113.20 Million	+13.54%
2007-12-31	NT$3.16 Billion ≈ $99.70 Million	+14.05%
2006-12-31	NT$2.77 Billion ≈ $87.42 Million	-2.26%
2005-12-31	NT$2.84 Billion ≈ $89.45 Million	+20.99%
2004-12-31	NT$2.35 Billion ≈ $73.93 Million	+13.88%
2003-12-31	NT$2.06 Billion ≈ $64.92 Million	+24.74%
2002-12-31	NT$1.65 Billion ≈ $52.05 Million	--

About Sinphar Pharmaceutical Co Ltd

TW:1734 Taiwan Biotechnology

Market Cap

$191.15 Million

NT$6.07 Billion TWD

Market Cap Rank

#16828 Global

#846 in Taiwan

Share Price

NT$31.90

Change (1 day)

+0.16%

52-Week Range

NT$30.05 - NT$32.85

All Time High

NT$65.35